Showing results (1141-1150 of 1,193) with videos related to
Sort By:
Pageof 120
Investigational New Drugs|February 7, 2019
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trialsDylan J Martini, Yuan Liu, Julie M Shabto, et al.ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2Michael G Yang, Zili Xiao, Rulin Zhao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 TrialSuzanne L Topalian, Shailender Bhatia, Asim Amin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.Nature Communications|March 23, 2023
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockadeCrismita Dmello, Junfei Zhao, Li Chen, et al.Nature Communications|July 28, 2018
FABP4 as a key determinant of metastatic potential of ovarian cancerKshipra M Gharpure, Sunila Pradeep, Marta Sans, et al.Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.Research Square|March 11, 2024
The BMAL1/HIF2A heterodimer modulates circadian variations of myocardial injuryWei Ruan, Tao Li, Jaewoong Lee, et al.Pageof 120